瑞拉莫林治疗糖尿病胃轻瘫的总体安全性:2a与2b期试验数据分析
本文汇总两项随机双盲2期试验(2a期204例、2b期393例糖尿病胃轻瘫成人)的安全性数据,描述性分析瑞拉莫林的不良事件与实验室指标。结果显示严重不良事件比例组间相近,但治疗中出现的不良事件导致停药的比例在瑞拉莫林组较高;2b期糖化血红蛋白与空腹血糖升高呈剂量相关。结论认为瑞拉莫林安全性可接受,但可能升高血糖,需主动管理。
要点
- 瑞拉莫林组严重不良事件比例与安慰剂组相近,但不良事件相关停药比例更高。
- 2b期糖化血红蛋白(P<0.0001)和空腹血糖(P=0.0043)升高呈剂量相关。
- 使用瑞拉莫林的患者应主动监测并管理血糖。
核心结论
- 瑞拉莫林在2期试验中显示可接受的安全性和耐受性。
- 瑞拉莫林可能升高血糖,对接受治疗的患者应主动管理血糖。
研究设计与样本
- 两项随机双盲2期试验(NCT01571297、NCT02357420)的安全性数据回顾性描述分析。
- 2a期204例、2b期393例18-75岁糖尿病胃轻瘫成人;2a期4周(瑞拉莫林10µg每日一次或两次、安慰剂每日两次),2b期12周(瑞拉莫林10、30或100µg或安慰剂每日两次),均设1-2周单盲安慰剂导入。
- 事后采用协方差分析评估治疗对糖化血红蛋白和血糖的影响。
主要发现
- 2a期和2b期女性分别占67%和62%,2型糖尿病分别占88%和89%。
- 严重不良事件比例及发生至少1例治疗中出现的不良事件(TEAE)的比例在各治疗组间相近。
- TEAE相关停药比例在瑞拉莫林组高于安慰剂组。
- 2a期12例严重TEAE中无任一患者发生超过1例;2b期有5例严重TEAE报告于超过1例患者,1例(100µg组)死亡(尿脓毒症),均与瑞拉莫林无关。
- 2b期糖化血红蛋白和空腹血糖升高呈剂量相关(P<0.0001和P=0.0043)。
关键数值与推荐
- 2b期糖化血红蛋白升高与剂量相关,P<0.0001。
- 2b期空腹血糖升高与剂量相关,P=0.0043。
临床怎么用
- 瑞拉莫林治疗期间应主动监测和管理血糖。
- 需关注不良事件导致的停药风险。
局限性
- 安全性分析为描述性,样本来自2期试验。
- 2a期与2b期试验时长不同(4周与12周)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Relamorelin, a pentapeptide ghrelin receptor agonist, accelerated gastric emptying significantly and improved symptoms in adults with diabetic gastroparesis in phase 2 trials. AIM: To assess the safety and tolerability of relamorelin across phase 2 trials. METHODS: Safety assessments in patients aged 18-75 years (weight, adverse events [AEs] and laboratory tests) from two randomised, double-blind phase 2 trials (NCT01571297, NCT02357420; results published previously) were reviewed descriptively. Analysis of covariance assessed treatment effect on glycated haemoglobin (HbA1c) and blood glucose post hoc. Phase 2a and 2b trial durations were, respectively, 4 weeks (relamorelin 10 µg once or twice daily [b.d.] or placebo b.d.) and 12 weeks (relamorelin 10, 30 or 100 µg or placebo b.d.) with 1- and 2-week, single-blind placebo run-ins. RESULTS: Among 204 phase 2a and 393 phase 2b patients, respectively, 67% and 62% were female, and 88% and 89% had type 2 diabetes. Proportions of patients reporting serious AEs were similar across treatment groups, as were those with ≥1 treatment-emergent AE (TEAE). TEAE-related discontinuations were proportionally higher in relamorelin groups than placebo. Of 12 serious TEAEs in phase 2a, none occurred in >1 patient. In phase 2b, five serious TEAEs were reported in >1 patient, and one (100 µg) died (urosepsis), all unrelated to relamorelin. In phase 2b, increased HbA1c and fasting blood glucose levels were dose-related (P < 0.0001 and P = 0.0043, respectively). CONCLUSIONS: Relamorelin showed acceptable safety and tolerability in phase 2 trials. Relamorelin may elevate blood glucose: this should be managed proactively in relamorelin-treated patients.
引用
- Camilleri M, Lembo A, McCallum R, et al. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. Aliment Pharmacol Ther. 2020. PMID: 32301137. doi:10.1111/apt.15711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。